Advertisement

Deciphering the Cirrhotic Patient’s Present Status: The Overlap Between Physical Frailty, Disability, and Sarcopenia

  • Elliot B. TapperEmail author
Chapter

Abstract

It is increasingly recognized that factors beyond traditional measures of liver severity like the Model for End-Stage Liver Disease such as disability, frailty, and sarcopenia are important predictors of meaningful outcomes for patients with cirrhosis. Although each concept is measured in different ways with clinical utility that is context dependent, they share a common biology. Understanding the overlap between these measures informs practice in important ways. Underlying each factor is malnutrition, deconditioning, and hepatic encephalopathy. Interventions to forestall or rehabilitate markers such as disability, frailty, and sarcopenia will require a deliberate, multimodal approach geared toward their specific drivers.

Keywords

Liver disease Cirrhosis Portal hypertension Hepatic encephalopathy Malnutrition 

Notes

Disclosure

  1. 1.

    Elliot Tapper is the guarantor of this article.

     
  2. 2.

    Funding: Elliot Tapper receives funding from the National Institutes of Health through the Michigan Institute for Clinical and Health Research (KL2TR002241).

     

References

  1. 1.
    Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634–56.CrossRefGoogle Scholar
  2. 2.
    Tapper EB, Konerman M, Murphy S, Sonnenday CJ. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. Am J Transplant. 2018;18:2566.CrossRefGoogle Scholar
  3. 3.
    Bajaj JS, Thacker LR, Heuman DM, Sterling RK, Stravitz RT, Sanyal AJ, et al. Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl. 2012;18(10):1179–87.CrossRefGoogle Scholar
  4. 4.
    Kumar A, Davuluri G, Engelen MP, Ten Have GA, Prayson R, Deutz NE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology. 2017;65(6):2045–58.CrossRefGoogle Scholar
  5. 5.
    van Vugt J, Levolger S, de Bruin R, van Rosmalen J, Metselaar H, IJzermans J. Systematic review and meta-analysis of the impact of computed tomography–assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant. 2016;16(8):2277–92.CrossRefGoogle Scholar
  6. 6.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.CrossRefGoogle Scholar
  7. 7.
    Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166–73, 73 e1.CrossRefGoogle Scholar
  8. 8.
    Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC, et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrology Dialysis Transplantation. 2015;30(10):1718–25.CrossRefGoogle Scholar
  9. 9.
    Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66(2):564–74.CrossRefGoogle Scholar
  10. 10.
    Lai JC, Covinsky KE, Hayssen H, Lizaola B, Dodge JL, Roberts JP, et al. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. Liver Int. 2015;35(9):2167–73.CrossRefGoogle Scholar
  11. 11.
    Lai JC, Covinsky KE, McCulloch CE, Feng S. The Liver Frailty Index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113(2):235.CrossRefGoogle Scholar
  12. 12.
    Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in patients with cirrhosis awaiting liver transplantation: results from the functional assessment in liver transplantation (FrAILT) study. Hepatology. 2016;63(2):574–80.CrossRefGoogle Scholar
  13. 13.
    Lai JC, Feng S, Terrault N, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14(8):1870–9.CrossRefGoogle Scholar
  14. 14.
    Samoylova ML, Covinsky KE, Haftek M, Kuo S, Roberts JP, Lai JC. Disability in patients with end-stage liver disease: results from the functional assessment in liver transplantation study. Liver Transpl. 2017;23(3):292–8.CrossRefGoogle Scholar
  15. 15.
    Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology. 2015;62(2):584–90.CrossRefGoogle Scholar
  16. 16.
    Orman ES, Ghabril M, Chalasani N. Poor performance status is associated with increased mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14(8):1189–95. e1.CrossRefGoogle Scholar
  17. 17.
    Tandon P, Reddy KR, O'leary JG, Garcia-Tsao G, Abraldes JG, Wong F, et al. A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis. Hepatology. 2017;65(1):217–24.CrossRefGoogle Scholar
  18. 18.
    Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. J Hepatol. 2018;69:818.CrossRefGoogle Scholar
  19. 19.
    Serper M, Bittermann T, Rossi M, Goldberg DS, Thomasson AM, Olthoff KM, et al. Functional status, healthcare utilization, and the costs of liver transplantation. Am J Transplant. 2018;18(5):1187–96.CrossRefGoogle Scholar
  20. 20.
    Dolgin NH, Martins PN, Movahedi B, Lapane KL, Anderson FA, Bozorgzadeh A. Functional status predicts postoperative mortality after liver transplantation. Clin Transpl. 2016;30(11):1403–10.CrossRefGoogle Scholar
  21. 21.
    Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, Boffo G, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition (Burbank, Los Angeles County, Calif). 2001;17(6):445–50.CrossRefGoogle Scholar
  22. 22.
    Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology (Baltimore, Md). 1996;23(5):1041–6.CrossRefGoogle Scholar
  23. 23.
    Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clinical nutrition (Edinburgh, Scotland). 2006;25(2):285–94.CrossRefGoogle Scholar
  24. 24.
    Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clinical nutrition (Edinburgh, Scotland). 1997;16(2):43–55.CrossRefGoogle Scholar
  25. 25.
    O'Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. Gastroenterology. 2008;134(6):1729–40.CrossRefGoogle Scholar
  26. 26.
    Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology (Baltimore, Md). 2013;58(1):325–36.CrossRefGoogle Scholar
  27. 27.
    Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology (Baltimore, Md). 2011;54(3):1063–70.CrossRefGoogle Scholar
  28. 28.
    Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106(6):1081–8.CrossRefGoogle Scholar
  29. 29.
    Owen OE, Trapp VE, Reichard GA Jr, Mozzoli MA, Moctezuma J, Paul P, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72(5):1821–32.CrossRefGoogle Scholar
  30. 30.
    Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology (Baltimore, Md). 2008;48(2):557–66.CrossRefGoogle Scholar
  31. 31.
    Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, et al. Screening for zinc deficiency in patients with cirrhosis: when should we start? Dig Dis Sci. 2015;60(10):3130–5.CrossRefGoogle Scholar
  32. 32.
    Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32(9):1080–90.CrossRefGoogle Scholar
  33. 33.
    Murphy SL, Tapper EB, Blackwood J, Richardson JK. Why do individuals with cirrhosis fall? a mechanistic model for fall assessment, treatment, and research. Dig Dis Sci. 2018:1–8.Google Scholar
  34. 34.
    Tapper EB, Martinez-Macias R, Duarte-Rojo A. Is exercise beneficial and safe in patients with cirrhosis and portal hypertension? Current Hepatology Reports. 2018:1–9.Google Scholar
  35. 35.
    Tapper EB, Jiang ZG, Patwardhan VR, editors. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clinic Proceedings, vol. 90: Elsevier; 2015. p. 646.Google Scholar
  36. 36.
    Nabi E, Thacker LR, Wade JB, Sterling RK, Stravitz RT, Fuchs M, et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol. 2014;12(8):1384–9. e2.CrossRefGoogle Scholar
  37. 37.
    Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011;140(2):478–87. e1.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyUniversity of MichiganAnn ArborUSA
  2. 2.Gastroenterology Section, VA Ann Arbor Healthcare SystemAnn ArborUSA

Personalised recommendations